Pedro García-Gómez

Pedro García-Gómez

Auto-generated profile, based on publicly available information

Pedro García-Gómez

Brain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in Nature Physics
Verified
Journal Article
Closed access
PDF file
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Gabriel Fernandez CalvoGabriel Fernandez Calvo
Gabriel Fernandez Calvo
JBJesús J. Bosque
Jesús J. Bosque
OLOdelaisy León-Triana
Odelaisy León-Triana
JJJuan Jiménez
Juan Jiménez
AVAna M. García Vicente
Ana M. García Vicente

11 April 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CMCátia Monteiro
Cátia Monteiro
LMLauritz Miarka
Lauritz Miarka
MPMaría Perea-García
María Perea-García
NPNeibla Priego
Neibla Priego
PGPedro García-Gómez
Pedro García-Gómez
MVManuel Valiente
Manuel Valiente
Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and the associated toxicity have questioned the clinical impact of this approach and emphasized the need for alternative treatments. Given the limited therapeutic options available for these patients and the poor understanding of the molecular mechanisms underlying the resistance of metastatic lesions to WBRT, we sought to uncover actionable targets and biomarkers that could help to refine patient selection. Through an unbiased analysis of experimental in vivo models of brain metastasis resistant to WBRT, we identified activation of the S100A9–RAGE–NF-κB–JunB pathway in brain metastases as a potential mediator of resistance in this organ. Targeting this pathway genetically or pharmacologically was sufficient to revert the WBRT resistance and increase therapeutic benefits in vivo at lower doses of radiation. In patients with primary melanoma, lung or breast adenocarcinoma developing brain metastasis, endogenous S100A9 levels in brain lesions correlated with clinical response to WBRT and underscored the potential of S100A9 levels in the blood as a noninvasive biomarker. Collectively, we provide a molecular framework to personalize WBRT and improve its efficacy through combination with a radiosensitizer that balances therapeutic benefit and toxicity.

7 November 2019 in Angiogenesis
Verified
Journal Article
Closed access
PDF file
PGPedro García-Gómez
Pedro García-Gómez
MVManuel Valiente
Manuel Valiente

17 February 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
LZLucía Zhu
Lucía Zhu
DRDiana Retana
Diana Retana
PGPedro García‐Gómez
Pedro García‐Gómez
LÁLaura Álvaro‐Espinosa
Laura Álvaro‐Espinosa
NPNeibla Priego
Neibla Priego
PNPilar Nicolás
Pilar Nicolás
We report a medium‐throughput drug‐screening platform (METPlatform) based on organotypic cultures that allows to evaluate inhibitors against metastases growing in situ . By applying this approach to the unmet clinical need of brain metastasis, we identified several vulnerabilities. Among them, a blood–brain barrier permeable HSP90 inhibitor showed high potency against mouse and human brain metastases at clinically relevant stages of the disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ proteomic analysis applied to metastases treated with the chaperone inhibitor uncovered a novel molecular program in brain metastasis, which includes biomarkers of poor prognosis and actionable mechanisms of resistance. Our work validates METPlatform as a potent resource for metastasis research integrating drug‐screening and unbiased omic approaches that is compatible with human samples. Thus, this clinically relevant strategy is aimed to personalize the management of metastatic disease in the brain and elsewhere.

14 March 2022 in Molecular Oncology
Verified
Journal Article
Open access
PGPedro García‐Gómez
Pedro García‐Gómez
IGIrene Golán
Irene Golán
MDMahsa S. Dadras
Mahsa S. Dadras
AMArtur Mezheyeuski
Artur Mezheyeuski
CBClaudia Bellomo
Claudia Bellomo
Laia CajaLaia Caja
Laia Caja
Glioblastoma (GBM) is the most aggressive and common glioma subtype, with a median survival of 15 months after diagnosis. Current treatments have limited therapeutic efficacy; thus, more effective approaches are needed. The glioblastoma tumoural mass is characterised by a small cellular subpopulation – glioblastoma stem cells (GSCs) – that has been held responsible for glioblastoma initiation, cell invasion, proliferation, relapse and resistance to chemo‐ and radiotherapy. Targeted therapies against GSCs are crucial, as is understanding the molecular mechanisms that govern the GSCs. Transforming growth factor β (TGFβ) signalling and reactive oxygen species (ROS) production are known to govern and regulate cancer stem cell biology. Among the differentially expressed genes regulated by TGFβ in a transcriptomic analysis of two different patient‐derived GSCs, we found NADPH oxidase 4 (NOX4) as one of the top upregulated genes. Interestingly, when patient tissues were analysed, NOX4 expression was found to be higher in GSCs versus differentiated cells. A functional analysis of the role of NOX4 downstream of TGFβ in several patient‐derived GSCs showed that TGFβ does indeed induce NOX4 expression and increases ROS production in a NOX4‐dependent manner. NOX4 downstream of TGFβ regulates GSC proliferation, and NOX4 expression is necessary for TGFβ‐induced expression of stem cell markers and of the transcription factor nuclear factor erythroid 2‐related factor 2 (NRF2), which in turn controls the cell’s antioxidant and metabolic responses. Interestingly, overexpression of NOX4 recapitulates the effects induced by TGFβ in GSCs: enhanced proliferation, stemness and NRF2 expression. In conclusion, this work functionally establishes NOX4 as a key mediator of GSC biology.

21 July 2023 in npj Systems Biology and Applications
Verified
Journal Article
Open access
PDF file
BOBeatriz Ocaña-Tienda
Beatriz Ocaña-Tienda
JPJulián Pérez-Beteta
Julián Pérez-Beteta
JJJuan Jiménez-Sánchez
Juan Jiménez-Sánchez
DMDavid Molina-García
David Molina-García
Ana Ortiz de MendivilAna Ortiz de Mendivil
Ana Ortiz de Mendivil
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Tumor growth is the result of the interplay of complex biological processes in huge numbers of individual cells living in changing environments. Effective simple mathematical laws have been shown to describe tumor growth in vitro, or simple animal models with bounded-growth dynamics accurately. However, results for the growth of human cancers in patients are scarce. Our study mined a large dataset of 1133 brain metastases (BMs) with longitudinal imaging follow-up to find growth laws for untreated BMs and recurrent treated BMs. Untreated BMs showed high growth exponents, most likely related to the underlying evolutionary dynamics, with experimental tumors in mice resembling accurately the disease. Recurrent BMs growth exponents were smaller, most probably due to a reduction in tumor heterogeneity after treatment, which may limit the tumor evolutionary capabilities. In silico simulations using a stochastic discrete mesoscopic model with basic evolutionary dynamics led to results in line with the observed data.